Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Gulnaz Iqbal, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Richard Brouwer, BSc, Sherin Varghese, MSc, BA, Stephen Schey, MBBS, Jindriska Lindsay, FRCPath, Janet Dunn, PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140937

Published: 2020

Journal Articles

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

Karthik Ramasamy, MBBS MRCP FRCPath PhD, Mark T Drayson, MB ChB, PhD FRCPath, Gulnaz Iqbal, PhD, Victoria Stalker, BSc, MA, Salma Akhtar, BSc, MSc, Janet Dunn, PhD, Stephen Schey, MBBS

Blood (2019) 134 (Supplement_1): 3135.

https://doi.org/10.1182/blood-2019-128157

Published: 2019

Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Blood (2018) 132 (20): 2115–2124.

https://doi.org/10.1182/blood-2018-07-862334

Published: 2018

Includes: Supplemental data

Journal Articles

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Blood (2018) 132 (20): 2154–2165.

https://doi.org/10.1182/blood-2018-05-849893

Published: 2018

Includes: Supplemental data

Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Blood (2017) 130 (Supplement 1): 267.

https://doi.org/10.1182/blood.V130.Suppl_1.267.267

Published: 2017

Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Blood (2017) 130 (Supplement 1): 1864.

https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864

Published: 2017

Journal Articles

CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis

Blood (2012) 120 (21): 326.

https://doi.org/10.1182/blood.V120.21.326.326

Published: 2012

Journal Articles

CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma

Chirag Acharya, MD, Mike Y Zhong, B.S., Yolanda Calle, PhD, Stephen Schey, MD, Michelle Chen, Daniel Tannenbaum, B.S., Michaela R Reagan, PhD, Irene M. Ghobrial, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2012) 120 (21): 1835.

https://doi.org/10.1182/blood.V120.21.1835.1835

Published: 2012

Journal Articles

Beta7 Integrins Regulate Podia Formation in Multiple Myeloma (MM) Cells for the Interaction with the Cellular and Non-Cellular Bone Marrow (BM) Stroma

Karthik Ramasamy, MBBS, MRCP, FRCPath, Henry Lekgetho, Mr, Jose Luis Orgaz, Dr, Amna Anwar, BSc, Victoria Sanz-Moreno, Dr, Majid A Kazmi, Stephen Schey, MD, Yolanda Calle, PhD

Blood (2012) 120 (21): 3979.

https://doi.org/10.1182/blood.V120.21.3979.3979

Published: 2012

Journal Articles

The Wiskott Aldrich Syndrome Protein (WASP) Is Involved in Dexamethasone-Signalling Pathways Leading to Apoptosis of Multiple Myeloma Cells and in Cell Adhesion Mediated Drug Resistance Against Dexamethasone

Hazera Khatun, Amna Anwar, BSc, Majid A. Kazmi, Stephen Schey, Yolanda Calle, PhD

Blood (2011) 118 (21): 1809.

https://doi.org/10.1182/blood.V118.21.1809.1809

Published: 2011

Journal Articles

Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,

Stephen Schey, MD, Sean Stern, Sujith Dhanasiri, Ruth Brown, MS, MHSA

Blood (2011) 118 (21): 4181.

https://doi.org/10.1182/blood.V118.21.4181.4181

Published: 2011

Journal Articles

CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma

Giulia Giunti, David Malone, Lucas Chan, Darling David, Shahram Y Kordasti, MD, PhD, Linda Barber, Oppenheim David, Farzin Farzaneh, DPhil, Stephen Schey

Blood (2011) 118 (21): 4718.

https://doi.org/10.1182/blood.V118.21.4718.4718

Published: 2011

Journal Articles

Novel In Vitro Experimental Platform for High Throughput Analysis of the Effect of Drugs on Multiple Myeloma Cells and the Tumour Microenvironment In a Co-Culture Setting

Karthik Ramasamy, MBBS, MRCP, FRCPath, Hazera Khatun, Lee Macpherson, Stephen Schey, MBBS, Yolanda Calle

Blood (2010) 116 (21): 982.

https://doi.org/10.1182/blood.V116.21.982.982

Published: 2010

Journal Articles

Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib

Karthik Ramasamy, MBBS, MRCP, FRCPath, Hazera Khatun, Lee Macpherson, Ghulam J. Mufti, DM, FRCP, FRCPath, Stephen Schey, MBBS, Yolanda Calle

Blood (2010) 116 (21): 1931.

https://doi.org/10.1182/blood.V116.21.1931.1931

Published: 2010

Journal Articles

Dual Src/Abl Kinase Targeted Inhibition in Myeloma Microenvironment Promotes Myeloma Cell Apoptosis Both in Vitro and In Vivo .

Karthik Ramasamy, Lee Macpherson, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Stephen Schey, Yolanda Calle, Ph.D.

Blood (2009) 114 (22): 2813.

https://doi.org/10.1182/blood.V114.22.2813.2813

Published: 2009

Journal Articles

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

Julian Gillmore, Kim Cocks, Simon DJ Gibbs, Prayman T Sattianayagam, Thirusha Lane, Helen Lachmann, Stephen Schey, James D. Cavenagh, Heather Oakervee, Gareth J Morgan, Atul B Mehta, Suzan Bourne, E. Skinner, G. Booth, Philip N Hawkins, Ashutosh D Wechalekar

Blood (2009) 114 (22): 2869.

https://doi.org/10.1182/blood.V114.22.2869.2869

Published: 2009

Journal Articles

CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

Stephen Schey, Gareth J Morgan, MD, PhD, Karthik Ramasamy, Beth Hazel, Karen Phekoo, Sophie Corderoy, Matthew Jenner, Faith Davies

Blood (2008) 112 (11): 3707.

https://doi.org/10.1182/blood.V112.11.3707.3707

Published: 2008

Journal Articles

Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).

Karthik Ramasamy, MD, Shameem Mahmood, MD, Laurence Pearce, MD, ZiYi Lim, MD, Dariusz Ladon, PhD, Antonio Pagliuca, MD, Stephen Devereux, MD, PhD, Ghulam J. Mufti, MD, DM, Stephen Schey, MD

Blood (2007) 110 (11): 3034.

https://doi.org/10.1182/blood.V110.11.3034.3034

Published: 2007

Journal Articles

Hepatocyte Growth Factor Expression in Bone Marrow Microenvironment Is Critical for Progression of MGUS to Myeloma.

Karthik Ramasamy, MD, Stephen Schey, MD, Ghulam J. Mufti, MD, DM, Farzin Farzaneh, PhD, Yolanda Calle, PhD

Blood (2007) 110 (11): 4766.

https://doi.org/10.1182/blood.V110.11.4766.4766

Published: 2007

Journal Articles

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

Gareth J. Morgan, PhD, Stephen Schey, MD, Ping Wu, M. Srikanth, MD, Karen J. Phekoo, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Faith E. Davies, MD

Blood (2006) 108 (11): 3555.

https://doi.org/10.1182/blood.V108.11.3555.3555

Published: 2006

NARROW

Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis

CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma

Beta7 Integrins Regulate Podia Formation in Multiple Myeloma (MM) Cells for the Interaction with the Cellular and Non-Cellular Bone Marrow (BM) Stroma

The Wiskott Aldrich Syndrome Protein (WASP) Is Involved in Dexamethasone-Signalling Pathways Leading to Apoptosis of Multiple Myeloma Cells and in Cell Adhesion Mediated Drug Resistance Against Dexamethasone

Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,

CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma

Novel In Vitro Experimental Platform for High Throughput Analysis of the Effect of Drugs on Multiple Myeloma Cells and the Tumour Microenvironment In a Co-Culture Setting

Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib

Dual Src/Abl Kinase Targeted Inhibition in Myeloma Microenvironment Promotes Myeloma Cell Apoptosis Both in Vitro and In Vivo .

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).

Hepatocyte Growth Factor Expression in Bone Marrow Microenvironment Is Critical for Progression of MGUS to Myeloma.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only